Association among serum perfluoroalkyl chemicals, glucose homeostasis, and metabolic syndrome in adolescents and adults

Diabetes Care

Volumn 32, Issue 4, 2009, Pages 702-707

  Lin, Chien Yu ^a,b,c   Chen, Pau Chung ^b   Lin, Yu Chuan ^b,d   Lin, Lian Yu ^e  

^a EN CHU KONG HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^d TAIPEI CITY HOSPITAL   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NONANOIC ACID; PERFLUORONONANOIC ACID; PERFLUOROOCTANOIC ACID; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; B LYMPHOCYTE; CONSUMER; CONTROLLED STUDY; FEMALE; GLUCOSE HOMEOSTASIS; GROUPS BY AGE; HEALTH SURVEY; HUMAN; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LYMPHOCYTE FUNCTION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PREVALENCE; RELIABILITY;

ADOLESCENT; ADULT; ALKANESULFONIC ACIDS; FEMALE; FLUOROCARBONS; HEALTH SURVEYS; HUMANS; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OCTANOIC ACIDS; REGRESSION ANALYSIS; YOUNG ADULT;

EID: 65349170042     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc08-1816     Document Type: Article

References (23)

1. Lau C, Anitole K, Hodes C, Lai D, Pfahles- Hutchens A, Seed J: Perfluoroalkyl acids: a review of monitoring and toxicological findings. Toxicol Sci 99:366-394, 2007
2. Calafat AM, Wong LY, KuklenyikZ, Reidy JA, Needham LL: Polyfluoroalkyl chemicals in the US population: data from the National Health and Nutrition Examination Survey (NHANES) 2003-2004 and comparisons with NHANES 1999-2000. Health Perspect 115:1596-1602, 2007
3. Kennedy GLJr, Butenhoff JL, Olsen GW, O'Connor JC, Seacat AM, Perkins RG, Biegel LB, Murphy SR, Farrar DG: The toxicology of perfluorooctanoate. Crit Rev Toxicol 34:351-384, 2004
4. Kropp T, Houlihan J: Evaluating human health risks from exposure to perfluorooctanoic acid (PFOA): recommendations to the Science Advisory Board's PFOA Review Panel [article online], 2005. Available from http://www.epa. gov/sab/pdf/kropp-ewg.pdf. Accessed 21 September 2008
5. Butenhoff J, Costa G, Elcombe C, Farrar D, Hansen K, Iwai H, Jung R, Kennedy G Jr, Lieder P, Olsen G, Thomford P: Toxicity of ammonium perfluorooctanoate in male cynomolgus monkeys after oral dosing for 6 months. Toxicol Sci 69:244-257, 2002
6. Alexander BH, Olsen GW, Burris JM, Mandel JH, Mandel JS: Mortality of employees of a perfluorooctanesulphonyl fluoride manufacturing facility. Occup Environ Med 60:722-729, 2003
7. Fei C, McLaughlinJK, Tarone RE, OlsenJ: Perfluorinated chemicals and fetal growth: a study within the Danish National Birth Cohort. Envir Health Persp 115:1677-1682, 2007
8. Intrasuksri U, Rangwala SM, O'Brien M, Noonan DJ, Feller DR: Mechanisms of peroxisome proliferation by perfluo-rooctanoic acid and endogenous fatty acids. Gen Pharmacol 31:187-197, 1998
9. Sohlenius AK, Eriksson AM, Hogstrom C, Kimland M, DePierre JW: Perfluorooctane sulfonic acid is a potent inducer of peroxisomal fatty acid β-oxidation and other activities known to be affected by peroxisome proliferators in mouse liver. Pharmacol Toxicol 72:90-93, 2003
10. The National Health and Nutrition Examination Surveys (NHANES) [article online], 2008. Available from http://www.cdc.gov/ nchs/about/major/nhanes/ currentnhanes. htm and http://www.cdc.gov/nchs/about/ major/nhanes/nhanes2003- 2004/current-hanes-03-04.htm. Accessed 21 September 2008
11. Weitzman M, Cook S, Auinger P, Florin TA, Daniels S, Nguyen M, Winickoff JP: Tobacco smoke exposure is associated with the metabolic syndrome in adolescents. Circulation 112:862-869, 2005
12. Diabetic Trial Unit, University of Oxford: HOMA calculator [article online], 2007. Available from http://www.dtu.ox.ac.uk/ index.php?maindoc=/homa/. Accessed 1 October 2008
13. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486-2497, 2001
14. Li C, Ford ES, Mokdad AH, Cook S: Recent trends in waist circumference and waist-height ratio among US children and adolescents. Pediatrics 118:e1390-e1398, 2006
15. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C: American Heart Association, National Heart, Lung, and Blood Institute: definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109:433-438, 2004
16. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents: The fourth report on the diagnosis, evaluation and treatment of high blood pressure in children and adolescents. Pediatrics 114:555-576, 2004
17. Kuklenyik Z, Needham LL, Calafat AM: Measurement of 18 perfluorinated organic acids and amides in human serum using on-line solid-phase extraction. Anal Chem 77:6085-6091, 2005
18. Inoue K, Okada F, Ito R, Kato S, Sasaki S, Nakajima S, Uno A, Saijo Y, Sata F, YoshimuraY, Kishi R, Nakazawa H: Perfluorooctane sulfonate (PFOS) and related perfluorinated compounds in human maternal and cord blood samples: assessment of PFOS exposure in a susceptible population during pregnancy. Environ Health Perspect 112:1204-1207, 2004
19. Olsen GW, Church TR, Hansen KJ, Burris JM, ButenhoffJL, MandelJH: Quantitative evaluation of perfluorooctanesulfonate (PFOS) and other fluorochemicals in the serum of children. J Child Health 2:53-76, 2004
20. Kudo N, Bandi N, Suzuki E, Katakura M, Kawashima Y: Induction by perfluorinated fatty acids with different carbon chain length of peroxisomal ( -oxidation in the liver of rats. Chem Biol Interact 124: 119-132, 2007
21. Kudo N, Suzuki-Nakajima E, Mitsumoto A, and Kawashima Y: Responses of the liver to perfluorinated fatty acids with different carbon chain length in male and female mice: in relation to induction of hepatomegaly, peroxisomal β-oxidation and microsomal 1-acylglycerophosphocholine acyltransferase. Biol Pharm Bull 29:1952-1957, 2006
22. Paumelle R, Staels B: Cross-talk between statins and PPARα in cardiovascular diseases: clinical evidence and basic mechanisms. Trends Cardiovasc Med 18:73-78, 2008
23. Luebker DJ, Hansen KJ, Bass NM, Butenhoff JL: Interactions of fluorochemicals with rat liver fatty acid-binding protein. Toxicology 176:175-185, 2002